SCHEMBL802120

SCHEMBL802120

Cc1ccccc1-c1cc(N2CCCCC2)nc(Nc2n[nH]c3ccccc23)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.42
GAA P10253 4/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
ACHE P22303 1/20 0.42
TDP1 Q9NUW8 2/20 0.41
ALDH1A1 P00352 4/20 0.40
CYP1A2 P05177 3/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.40
HPGD P15428 3/20 0.39
POLB P06746 2/20 0.39
ALOX12 P18054 1/20 0.39
SMYD2 Q9NRG4 1/20 0.38
PDPK1 O15530 1/20 0.38
PIK3CA P42336 2/20 0.38
EGFR P00533 2/20 0.37
HSD17B10 Q99714 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL802717 0.91 CYP1A2 (0.50) KDM4EALDH1A1CYP1A2KMT2AMEN1
SCHEMBL802383 0.88 FADS1 (0.41) L3MBTL1ALDH1A1CYP1A2KMT2AMEN1
SCHEMBL805602 0.85 CYP1A2 (0.41) CYP1A2CYP2C19PDPK1PIK3CA
SCHEMBL801684 0.82 EGFR (0.39) KMT2AMEN1POLBSMYD2EGFR
SCHEMBL802094 0.82 PIK3CA (0.45) GAAL3MBTL1ALDH1A1CYP1A2KMT2A
SCHEMBL801695 0.81 GALR2 (0.37) ALDH1A1CYP1A2KMT2AMEN1CYP2D6
SCHEMBL802710 0.81 GSK3A (0.42) ALDH1A1SMYD2EGFR
SCHEMBL802734 0.81 AURKA (0.50)
SCHEMBL801694 0.80 VCP (0.43) KDM4EGAATDP1ALDH1A1CYP1A2
SCHEMBL13055223 0.79 FADS1 (0.35) PDPK1PIK3CAEGFRKDRSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed
US-20100256170-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256170-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, CDK3, GSK3A KDM4E 1621/4885GAA 4421/4885L3MBTL1 3003/4885
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 KDM4E 1040/4885GAA 2990/4885L3MBTL1 3025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.